Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.

Dig Dis Sci 2016 12 14;61(12):3602-3608. Epub 2016 Oct 14.

Department of Medicine, San Francisco General Hospital, University of California San Francisco, 1001 Potrero Avenue, NH 3-D, San Francisco, CA, 94110, USA.

Background: Vulnerable populations are disproportionately affected by hepatitis C virus (HCV) infection and experience high rates of health disparity. There are no data on real-world experience with highly efficacious direct-acting anti-HCV treatment in this population.

Aims: We aimed to evaluate the real-world experience with sofosbuvir-based regimens among a vulnerable HCV-infected population.

Methods: HCV treatment response was assessed among 204 patients who completed 12-24 weeks of sofosbuvir-based regimens (in combination with pegylated interferon and ribavirin, simeprevir, ledipasvir, or daclatasvir) at the San Francisco safety-net healthcare system liver specialty clinic between January 2014 and December 2015. Virologic response during therapy was assessed at weeks 4 and 8, end of therapy, and 12-week treatment discontinuation (SVR 12).

Results: Patient characteristics were median age 58 years, 60 % male, 42 % Caucasian (21 % black, 19 % Hispanic), 72 % had genotype 1 (23 % genotype 2 or 3), and the median baseline log HCV viral load was 6.1 IU/ml and alanine transaminase 63 U/l. Cirrhosis was present in 36 % (of whom 40 % were decompensated), and 18 % were HCV treatment-experienced. Overall, SVR 12 was achieved in 97 % (99 % genotype 1, 100 % genotype 2, 84 % genotype 3). Five of six (83 %) patients who relapsed had decompensated cirrhosis, and 67 % were also non-adherent to therapy. On-treatment virologic response did not impact SVR.

Conclusions: High rates of sustained virologic response can be achieved in safety-net HCV-infected patients. Access to DAA-based regimens is critical to addressing HCV-related health disparity in this at-risk population.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-016-4340-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106301PMC
December 2016
37 Reads

Publication Analysis

Top Keywords

real-world experience
12
virologic response
12
health disparity
8
sofosbuvir-based regimens
8
high rates
8
genotype
5
19 % hispanic
4
black 19 %
4
21 % black
4
58 years 60 %
4
age 58 years
4
60 % male
4
male 42 %
4
42 % caucasian
4
caucasian 21 %
4
hispanic 72 %
4
baseline log
4
log hcv
4
hcv viral
4
viral load
4

References

(Supplied by CrossRef)

Centers for Disease Control et al.
MMWR 2011

GL Davis et al.
Gastroenterology 2010

H Razavi et al.
Hepatology 2013

S Saab et al.
Am J Gastroenterol 2014

AG Singal et al.
JGIM 2012

GC Nguyen et al.
Hepatology 2007

RC Quillin III et al.
Clin Gastroenterol Hepatol 2014

VA Moyer et al.
Ann Intern Med 2013

D Bumenthal et al.
N Engl J Med 2014

Similar Publications